PMID- 30705945
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2364-3722 (Print)
IS  - 2196-9736 (Electronic)
IS  - 2196-9736 (Linking)
VI  - 7
IP  - 2
DP  - 2019 Feb
TI  - Durability and long-term outcomes of direct EUS-guided gastroenterostomy using 
      lumen-apposing metal stents for gastric outlet obstruction.
PG  - E144-E150
LID - 10.1055/a-0799-9939 [doi]
AB  - Background and study aims  EUS-guided gastroenterostomy (GE) is a novel, 
      minimally invasive endoscopic procedure for the treatment of gastric outlet 
      obstruction (GOO). The direct-EUS-GE (D-GE) approach has recently gained 
      traction. We aimed to report on a large cohort of patients who underwent DGE with 
      focus on long-term outcomes. Patients and methods  This two-center, retrospective 
      study involved consecutive patients who underwent D-GE between October 2014 and 
      May 2018. The primary outcomes were technical and clinical success. Secondary 
      outcomes were adverse events (AEs), rate of reintervention, procedure time, time 
      to resume oral diet, and post-procedure length of stay (LOS). Results  A total of 
      57 patients (50.9 % female; median age 65 years) underwent D-GE for GOO. The 
      etiology was malignant in 84.2 % and benign in 15.8 %. Technical success and 
      clinical success were achieved in 93 % and 89.5 % of patients, respectively, with 
      a median follow-up of 196 days in malignant GOO and 319.5 days in benign GOO. 
      There were 2 (3.5 %) AEs, one severe and one moderate. Median procedure time was 
      39 minutes (IQR, 26 - 51.5 minutes). Median time to resume oral diet after D-GE 
      was 1 day (IQR 1 - 2 days). Median post D-GE LOS was 3 days (IQR 2 - 7 days). 
      Rate of reintervention was 15.1 %. Conclusions  D-GE is safe and effective in 
      management of both malignant and benign causes of GOO. Clinical success with D-GE 
      is durable with a low rate of reintervention based on a long-term cohort.
FAU - Kerdsirichairat, Tossapol
AU  - Kerdsirichairat T
AD  - Division of Gastroenterology and Hepatology, Johns Hopkins Hospital, Baltimore, 
      Maryland, United States.
FAU - Irani, Shayan
AU  - Irani S
AD  - Division of Gastroenterology and Hepatology, Virginia Mason Medical Center, 
      Seattle, Washington, United States.
FAU - Yang, Juliana
AU  - Yang J
AD  - Division of Gastroenterology and Hepatology, Johns Hopkins Hospital, Baltimore, 
      Maryland, United States.
FAU - Brewer Gutierrez, Olaya I
AU  - Brewer Gutierrez OI
AD  - Division of Gastroenterology and Hepatology, Johns Hopkins Hospital, Baltimore, 
      Maryland, United States.
FAU - Moran, Robert
AU  - Moran R
AD  - Division of Gastroenterology and Hepatology, Johns Hopkins Hospital, Baltimore, 
      Maryland, United States.
FAU - Sanaei, Omid
AU  - Sanaei O
AD  - Division of Gastroenterology and Hepatology, Johns Hopkins Hospital, Baltimore, 
      Maryland, United States.
FAU - Dbouk, Mohamad
AU  - Dbouk M
AD  - Division of Gastroenterology and Hepatology, Johns Hopkins Hospital, Baltimore, 
      Maryland, United States.
FAU - Kumbhari, Vivek
AU  - Kumbhari V
AD  - Division of Gastroenterology and Hepatology, Johns Hopkins Hospital, Baltimore, 
      Maryland, United States.
FAU - Singh, Vikesh K
AU  - Singh VK
AD  - Division of Gastroenterology and Hepatology, Johns Hopkins Hospital, Baltimore, 
      Maryland, United States.
FAU - Kalloo, Anthony N
AU  - Kalloo AN
AD  - Division of Gastroenterology and Hepatology, Johns Hopkins Hospital, Baltimore, 
      Maryland, United States.
FAU - Khashab, Mouen A
AU  - Khashab MA
AD  - Division of Gastroenterology and Hepatology, Johns Hopkins Hospital, Baltimore, 
      Maryland, United States.
LA  - eng
PT  - Journal Article
DEP - 20190130
PL  - Germany
TA  - Endosc Int Open
JT  - Endoscopy international open
JID - 101639919
PMC - PMC6353651
COIS- Competing interests Dr Irani is a consultant for Boston Scientific. Dr Kumbhari 
      is a consultant for ReShape Life Sciences, Apollo Endosurgery, Medtronic, and 
      Boston Scientific, and receives consulting fees from Pentax Medical and C2 
      Therapeutics. Dr Kalloo is a founding member and equity holder for Apollo 
      Endosurgery. Dr Khashab is a consultant and on medical advisory board for Boston 
      Scientific and Olympus America and a consultant for Medtronic.
EDAT- 2019/02/02 06:00
MHDA- 2019/02/02 06:01
PMCR- 2019/02/01
CRDT- 2019/02/02 06:00
PHST- 2018/09/12 00:00 [received]
PHST- 2018/11/09 00:00 [accepted]
PHST- 2019/02/02 06:00 [entrez]
PHST- 2019/02/02 06:00 [pubmed]
PHST- 2019/02/02 06:01 [medline]
PHST- 2019/02/01 00:00 [pmc-release]
AID - 10.1055/a-0799-9939 [doi]
PST - ppublish
SO  - Endosc Int Open. 2019 Feb;7(2):E144-E150. doi: 10.1055/a-0799-9939. Epub 2019 Jan 
      30.